ADVFN Logo
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover
Premium Connexion/S'inscrire Profile Icon
CAC 40
7 346,15
(
0,48%
)
Dow Jones
36 245,50
(
0,82%
)
DAX
16 397,52
(
1,12%
)
Brent Oil
79,125
(
0,0%
)
Bitcoin
38 815,03
(
0,28%
)
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. AMEX
  6. AIM ImmunoTech Inc (AIM)

  7. AIM ImmunoTech Inc (AIM) Actualités

AIM AIM ImmunoTech Inc

0,48
0,01 (2,13%)
01 Déc 2023 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
AIM ImmunoTech Inc AIM AMEX Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,01 2,13% 0,48 22:27:48
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
0,48 0,4601 0,49 0,48 0,47
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
28/11/202322:54EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
28/11/202322:30BWAIM ImmunoTech Provides Update Regarding Annual Meeting
27/11/202318:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/11/202315:05GLOBEAIM ImmunoTech Bolsters Intellectual Property Estate for..
21/11/202318:00GLOBEAIM ImmunoTech Completes Treatment of Last Subject in Phase..
20/11/202323:29EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
20/11/202315:05EDGAR2Form DFAN14A - Additional definitive proxy soliciting..
20/11/202313:30EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
16/11/202315:21EDGAR2Form DFAN14A - Additional definitive proxy soliciting..
15/11/202313:30EDGAR2Form 8-K - Current report
15/11/202313:30GLOBEAIM ImmunoTech Reports Third Quarter 2023 Financial Results..
14/11/202316:00GLOBEAIM ImmunoTech Announces Publication of Data from Roswell..
09/11/202314:05GLOBEAIM ImmunoTech to Discuss Third Quarter 2023 Financial..
08/11/202322:15EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
08/11/202314:45EDGAR2Form 8-K - Current report
08/11/202314:45GLOBEAIM ImmunoTech Announces Encouraging Translational Data from..
07/11/202312:03EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
06/11/202315:25BWAIM ImmunoTech Files Definitive Proxy Statement and Sends..
06/11/202315:09EDGAR2Form DEFC14A - Definitive proxy statement, contested..
01/11/202322:01EDGAR2Form DEFC14A - Definitive proxy statement, contested..
30/10/202313:55GLOBEAIM ImmunoTech Announces Abstract Accepted for Poster..
24/10/202323:00EDGAR2Form PRER14A - Preliminary Proxy Soliciting materials
17/10/202314:45GLOBEAIM ImmunoTech Engages Business Development Firm, Azenova,..
13/10/202322:57EDGAR2Form PREC14A - Preliminary proxy statements, contested..
10/10/202315:00EDGAR2Form PREC14A - Preliminary proxy statements, contested..
29/9/202321:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/9/202313:00EDGAR2Form 8-K - Current report
22/9/202315:10EDGAR2Form 8-K - Current report
22/9/202315:05GLOBEAIM ImmunoTech Selected to Present at the 3rd Annual Marie..
11/9/202319:00GLOBEAIM ImmunoTech Announces Report of Complete Topline Data..
05/9/202315:05GLOBEAIM ImmunoTech to Present at the H.C. Wainwright 25th Annual..
28/8/202318:52EDGAR2Form DFAN14A - Additional definitive proxy soliciting..
28/8/202312:36EDGAR2Form SC 13D/A - General statement of acquisition of..
25/8/202320:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/8/202322:30EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
23/8/202314:51EDGAR2Form 8-K - Current report
23/8/202314:00BWAIM ImmunoTech Rejects Director Nomination Notice from..
15/8/202313:00EDGAR2Form 8-K - Current report
15/8/202312:45GLOBEAIM ImmunoTech Reports Second Quarter Financial Results and..
14/8/202323:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/8/202315:05GLOBEAIM ImmunoTech to Discuss Second Quarter 2023 Financial..
08/8/202314:05GLOBEAIM ImmunoTech Announces Completion of Enrollment in Phase 2..
07/8/202322:15EDGAR2Form SC 13D/A - General statement of acquisition of..
27/7/202323:01EDGAR2Form SC 13D - General statement of acquisition of beneficial..
19/7/202301:30GLOBEAIM ImmunoTech Issues Notice that an Unaffiliated Third..
18/7/202301:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/7/202322:45EDGAR2Form 8-K - Current report
10/7/202314:05GLOBEAIM ImmunoTech Enrolls and Doses First Subject in Phase 2..
05/7/202314:35GLOBEAIM ImmunoTech to Participate in the Virtual Investor Summer..
03/7/202314:42EDGAR2Form S-8 - Securities to be offered to employees in employee..

Dernières Valeurs Consultées

AMEX
AIM
AIM ImmunoTech
Delayed Upgrade Clock

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

Support: support@advfn.fr